FDA rejects Eiger’s emergency use request for repurposed Covid-19 treatment

Eiger BioPharmaceuticals is no longer planning to submit an emergency use application to the FDA. The Palo Alto, CA-based biotech had hoped to repurpose its hepatitis D treatment, peginterferon lambda, for mild-to-moderate Covid-19 — submitting a request to the FDA for a pre-EUA meeting back in September with data from…

…